
Modest setback for Sun Pharma, 18% fall in SPARC shares as drug fails to deliver
Sun Pharma announced results for its clinical trial program SCD-044 which failed to meet the end point in a Phase-2 trial and is discontinuing the program. While the stock of Sun Pharma reacted modestly to the news (declined by -0.6 per cent), the stock of …